GEMSOL
Sponsors
Esperas Pharma Inc., Esperas Pharma Inc., Bristol-Myers Squibb Services Unlimited Company, Medical University Of Vienna, Humanitas Mirasole S.p.A.
Conditions
Advanced or Metastatic CancerBladder Cancer
Muscle-Invasive Bladder CancerBladder cancerRecurrent Metastatic Nasopharingeal Carcinoma
Phase 2
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer with a Focus on Ovarian Cancer
CompletedCTIS2023-503459-91-00
Start: 2023-11-21End: 2025-04-07Target: 12Updated: 2025-03-17
COBRA - Chemoablation for Low Grade Bladder Cancer: A single arm, prospective, open-label, investigator-initiated Phase 2 study
RecruitingCTIS2024-517106-28-00
Start: 2023-12-27Target: 47Updated: 2024-10-30
Phase 3
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus
Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-
986205, Followed by Continued Post- Surgery Therapy with Nivolumab or
Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder
Cancer
Active, not recruitingCTIS2024-512158-12-00
Start: 2018-12-14Target: 386Updated: 2025-10-20
Toripalimab plus chemotherapy as first-line treatment for recurrent and/or metastatic nasopharyngeal cancer: safety and activity in non-endemic population
Not yet recruitingCTIS2025-522472-85-00
Target: 49Updated: 2026-01-08